Clinical Trials Logo

Retinopathy of Prematurity (ROP) clinical trials

View clinical trials related to Retinopathy of Prematurity (ROP).

Filter by:

NCT ID: NCT04506619 Terminated - Clinical trials for Bronchopulmonary Dysplasia

Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants

Start date: September 9, 2020
Phase:
Study type: Observational

The purpose of this study is to evaluate long-term safety and efficacy outcomes following previously administered short-term exposure to SHP607, as compared to a standard neonatal care group.

NCT ID: NCT04015180 Active, not recruiting - Clinical trials for Retinopathy of Prematurity (ROP)

Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090

FIREFLEYE next
Start date: March 18, 2020
Phase: Phase 3
Study type: Interventional

This is a follow-up study to evaluate the long term outcome of babies treated in the FIREFLEYE study.

NCT ID: NCT04004208 Completed - Clinical trials for Retinopathy of Prematurity (ROP)

Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy

FIREFLEYE
Start date: September 25, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate how well aflibercept works in babies with ROP, comparing it with laser therapy. The study also has the objective to demonstrate how safe aflibercept is when used in babies, and describe how the drug moves into, through and out of the body.

NCT ID: NCT03253263 Recruiting - Clinical trials for Bronchopulmonary Dysplasia

A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants

Start date: May 9, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if an investigational drug can prevent Bronchopulmonary Dysplasia, reducing the burden of chronic lung disease in extremely premature infants, as compared to extremely premature infants receiving standard neonatal care alone.

NCT ID: NCT02640664 Completed - Clinical trials for Retinopathy of Prematurity (ROP)

Rainbow Extension Study

RainbowExt
Start date: June 16, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the long term efficacy and safety of intravitreal ranibizumab compared with laser ablation therapy in patients who were treated for retinopathy of prematurity (ROP) in the core study CRFB002H2301 (NCT02375971)

NCT ID: NCT02386839 Completed - Clinical trials for Retinopathy of Prematurity (ROP)

Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP)

PEDAL
Start date: March 26, 2015
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the long-term efficacy and safety outcomes following short-term exposure to rhIGF-1/rhIGFBP-3 versus standard neonatal care in Study ROPP-2008-01 (NCT01096784).

NCT ID: NCT02134457 Completed - Clinical trials for Retinopathy of Prematurity (ROP)

Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity

CARE-ROP
Start date: August 2014
Phase: Phase 2
Study type: Interventional

This study is designed as an exploratory study to assess safety and efficacy of two different doses of the anti-VEGF agent ranibizumab (0.12 mg vs. 0.20 mg) in the treatment of infants with retinopathy of prematurity. Furthermore it shall help to improve safety in the treatment of ROP and provide explorative data on long-term effects of ranibizumab after intravitreal injection in neonates. The primary objective is to assess clinical efficacy of ranibizumab in children with ROP

NCT ID: NCT01954082 Terminated - Clinical trials for Retinopathy of Prematurity (ROP)

Inositol to Reduce Retinopathy of Prematurity

INS-3
Start date: April 17, 2014
Phase: Phase 3
Study type: Interventional

This is a Phase 3, randomized, double-masked, placebo-controlled study designed to determine the effectiveness of myo-Inositol 5% Injection to increase the incidence of survival without severe Retinopathy of Prematurity (ROP) through acute/final ROP determination up to 55 weeks postmenstrual age (PMA) in premature infants <28 0/7 weeks' gestation.

NCT ID: NCT01470430 Withdrawn - Clinical trials for Retinopathy of Prematurity (ROP)

VEGF In Systemic Circulation Of ROP-infants

Start date: March 2012
Phase: N/A
Study type: Observational

The purpose of this study is to measure systemic levels of vascular endothelial growth factor (VEGF) and other proteins (e.g. IGF-1) in the systemic circulation of infants with retinopathy of prematurity (ROP) following ocular treatment with either intravitreal injections of anti-VEGF agents or retinal laser photocoagulation. The primary aim is to determine if serum VEGF levels change after treatment.

NCT ID: NCT01096784 Completed - Clinical trials for Retinopathy of Prematurity (ROP)

IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity

Start date: June 18, 2010
Phase: Phase 2
Study type: Interventional

To compare the severity of retinopathy of prematurity (ROP) among treated infants with an untreated control population, matched for gestational age at birth while confirming the dose of rhIGF-1/rhIGFBP-3 is safe and efficacious.